Atopic Dermatitis (AD)

Immunology
11
Pipeline Programs
10
Companies
10
Clinical Trials
3 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
1
4
0
0
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
467%
Small Molecule
233%
+ 7 programs with unclassified modality

On Market (1)

Approved therapies currently available

Regeneron
DUPIXENTApproved
dupilumab
Regeneron
Interleukin-4 Receptor alpha Antagonist [EPC]injection2017

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Regeneron
RegeneronTARRYTOWN, NY
2 programs
1
DupilumabPhase 4Monoclonal Antibody
dupilumabN/AMonoclonal Antibody
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
DupilumabPhase 4Monoclonal Antibody
Enveda Biosciences
Enveda BiosciencesCO - Boulder
2 programs
1
1
ENV-294Phase 21 trial
ENV-294 CapsulePhase 11 trial
Active Trials
NCT07336940Active Not Recruiting16Est. Mar 2026
NCT07298395Recruiting64Est. Dec 2026
CAGE Bio
CAGE BioCA - San Carlos
2 programs
2
CGB-500 Ointment with 1% tofacitinibPhase 2Small Molecule1 trial
CGB-500 with 0.5% tofacitinibPhase 2Small Molecule1 trial
Active Trials
NCT06923228Not Yet RecruitingEst. Sep 2025
NCT06810050RecruitingEst. Oct 2025
Sanofi
SanofiPARIS, France
1 program
1
DupilumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT01979016Completed54Est. Jan 2015
Leadingtac Pharmaceutical
1 program
1
LT-002-158 tabletsPhase 1/21 trial
Active Trials
NCT06931990Not Yet RecruitingEst. Dec 2025
Generate Biomedicines
Generate BiomedicinesSOMERVILLE, MA
1 program
1
GB-7624Phase 11 trial
Active Trials
NCT06920693Active Not RecruitingEst. Dec 2026
Zai Lab
Zai LabCA - South SF
1 program
1
ZL-1503Phase 11 trial
Active Trials
NCT07235384Recruiting84Est. Dec 2027
Pierre Fabre
Pierre FabreFrance - Aignan
2 programs
Sunscreen RV4620A RP2552N/A1 trial
Sunscreen RV4620A RP2552N/A1 trial
Active Trials
NCT07194421Completed42Est. Feb 2024
NCT07194408Completed22Est. Feb 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Enveda BiosciencesENV-294
CAGE BioCGB-500 Ointment with 1% tofacitinib
CAGE BioCGB-500 with 0.5% tofacitinib
SanofiDupilumab
Leadingtac PharmaceuticalLT-002-158 tablets
Zai LabZL-1503
Enveda BiosciencesENV-294 Capsule
Generate BiomedicinesGB-7624
Pierre FabreSunscreen RV4620A RP2552
Pierre FabreSunscreen RV4620A RP2552

Clinical Trials (10)

Total enrollment: 282 patients across 10 trials

NCT07298395Enveda BiosciencesENV-294

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

Start: Dec 2025Est. completion: Dec 202664 patients
Phase 2Recruiting
NCT06923228CAGE BioCGB-500 Ointment with 1% tofacitinib

A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis

Start: Apr 2025Est. completion: Sep 2025
Phase 2Not Yet Recruiting
NCT06810050CAGE BioCGB-500 with 0.5% tofacitinib

Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis

Start: Dec 2024Est. completion: Oct 2025
Phase 2Recruiting
NCT01979016SanofiDupilumab

Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)

Start: Dec 2013Est. completion: Jan 201554 patients
Phase 2Completed
NCT06931990Leadingtac PharmaceuticalLT-002-158 tablets

A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis

Start: Apr 2025Est. completion: Dec 2025
Phase 1/2Not Yet Recruiting
NCT07235384Zai LabZL-1503

A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis

Start: Dec 2025Est. completion: Dec 202784 patients
Phase 1Recruiting
NCT07336940Enveda BiosciencesENV-294 Capsule

Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis

Start: Sep 2025Est. completion: Mar 202616 patients
Phase 1Active Not Recruiting
NCT06920693Generate BiomedicinesGB-7624

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult Participants

Start: Mar 2025Est. completion: Dec 2026
Phase 1Active Not Recruiting
NCT07194408Pierre FabreSunscreen RV4620A RP2552

In-Use Tolerance Study Under Dermatological and Pediatric Controls of Sunscreen in Children With Atopic Dermatitis

Start: Dec 2023Est. completion: Feb 202422 patients
N/ACompleted
NCT07194421Pierre FabreSunscreen RV4620A RP2552

In-Use Tolerance & Efficacy Study Under Dermatological Control of Sunscreen in Adults With Atopic Dermatitis Skin

Start: Oct 2023Est. completion: Feb 202442 patients
N/ACompleted

Related Jobs in Immunology

Regulatory Affairs Manager(Immunology), Korea

AbbVie
Seoul, Seoul
6h ago

Regional Sales Trainer - Rheumatology (Mid Atlantic/Central)

AbbVie
Remote
7h ago

Product Specialist - Immunology

Johnson & Johnson
Kibbutz Shefayim, Center District, Israel
20h ago

Senior Area Business Specialist, Immunology - Detroit, MI - Johnson & Johnson Innovative Medicine

Johnson & Johnson
Detroit, Michigan, United States
20h ago

Senior Medical Science Liaison, Dermatology - Indianapolis

Johnson & Johnson
Indianapolis, Indiana, United States
20h ago
$137K - $236K/yr

Field Reimbursement Manager - Rheumatology - Seattle, WA (North)

Johnson & Johnson
Seattle, Washington, United States of America
20h ago
$100K - $175K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 282 patients
10 companies competing in this space

Related Indications

Rheumatoid Arthritis(475)Psoriasis(206)Ulcerative Colitis(151)Atopic Dermatitis(144)Crohn's Disease(140)Systemic Lupus Erythematosus(85)Arthritis, Rheumatoid(61)Plaque Psoriasis(53)Crohn Disease(49)Ankylosing Spondylitis(33)